TCF responsive element
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 19, 2003
Grant Date -
Nov 7, 2002
app pub date -
Mar 2, 2001
filing date -
Mar 2, 2000
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Disclosed are DNA elements and constructs useful for obtaining tumour-selective gene expression in tumours having a mutated .beta.-catenin/APC pathway. In particular, the use of these constructs to express genes encoding therapeutic proteins in colorectal cancer cells is described. The constructs comprise multiple repeats of a TCF-binding element operably linked to a promoter. By means of such a construct, tumour cell-specific expression of a prodrug-converting enzyme such as nitroreductase may be achieved. Coupled with systemic administration of a suitable prodrug, such as CB1954, selective killing of such tumour cells can be demonstrated.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully